Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks (Nasdaq: ZYME) has announced its participation in six major healthcare investor conferences throughout November and December 2024. The clinical-stage biotechnology company will engage in various activities including one-on-one meetings, fireside chats, and panel discussions. The conferences include the UBS Global Healthcare Conference, Stifel Healthcare Conference, Jefferies London Healthcare Conference, Piper Sandler Healthcare Conference, Citi's Global Healthcare Conference, and the Evercore HealthCONx Conference. At Citi's conference, management will participate in a panel discussion on 'Novel Antibody Mechanisms in Oncology'.
Zymeworks (Nasdaq: ZYME) ha annunciato la sua partecipazione a sei importanti conferenze per investitori nel settore sanitario che si svolgeranno tra novembre e dicembre 2024. La compagnia di biotecnologie in fase clinica prenderà parte a diverse attività, incluse riunioni individuali, discussioni informali e tavole rotonde. Le conferenze includono la UBS Global Healthcare Conference, la Stifel Healthcare Conference, la Jefferies London Healthcare Conference, la Piper Sandler Healthcare Conference, la Citi's Global Healthcare Conference e la Evercore HealthCONx Conference. Durante la conferenza di Citi, il management parteciperà a una tavola rotonda dal titolo 'Meccanismi Anticorpali Innovativi in Oncologia'.
Zymeworks (Nasdaq: ZYME) ha anunciado su participación en seis importantes conferencias de inversionistas del sector salud que se llevarán a cabo durante noviembre y diciembre de 2024. La empresa de biotecnología en etapa clínica se involucrará en diversas actividades, incluyendo reuniones individuales, charlas informales y paneles de discusión. Las conferencias incluyen la UBS Global Healthcare Conference, la Stifel Healthcare Conference, la Jefferies London Healthcare Conference, la Piper Sandler Healthcare Conference, la Citi's Global Healthcare Conference y la Evercore HealthCONx Conference. En la conferencia de Citi, la dirección participará en un panel de discusión sobre 'Mecanismos Nuevos de Anticuerpos en Oncología'.
Zymeworks (Nasdaq: ZYME)는 2024년 11월과 12월에 열리는 6개의 주요 헬스케어 투자자 회의에 참여한다고 발표했습니다. 임상 단계의 바이오테크 회사는 일대일 미팅, 파이어사이드 챗, 패널 토론 등 다양한 활동에 참여할 예정입니다. 회의에는 UBS Global Healthcare Conference, Stifel Healthcare Conference, Jefferies London Healthcare Conference, Piper Sandler Healthcare Conference, Citi's Global Healthcare Conference, Evercore HealthCONx Conference가 포함됩니다. Citi의 회의에서는 경영진이 '종양학에서의 새로운 항체 메커니즘'에 대한 패널 토론에 참여할 예정입니다.
Zymeworks (Nasdaq: ZYME) a annoncé sa participation à six grandes conférences d'investisseurs dans le secteur de la santé qui se dérouleront en novembre et décembre 2024. L'entreprise de biotechnologie en phase clinique s'engagera dans diverses activités, y compris des réunions individuelles, des discussions informelles et des tables rondes. Les conférences incluent la UBS Global Healthcare Conference, la Stifel Healthcare Conference, la Jefferies London Healthcare Conference, la Piper Sandler Healthcare Conference, la Citi's Global Healthcare Conference et la Evercore HealthCONx Conference. Lors de la conférence de Citi, la direction participera à une table ronde sur 'Mécanismes d'Anticorps Nouveaux en Oncologie'.
Zymeworks (Nasdaq: ZYME) hat die Teilnahme an sechs wichtigen Investorenkonferenzen im Gesundheitsbereich für November und Dezember 2024 angekündigt. Das biopharmazeutische Unternehmen in der klinischen Phase wird an verschiedenen Aktivitäten teilnehmen, darunter Einzelgespräche, informelle Gespräche am Kamin und Podiumsdiskussionen. Zu den Konferenzen gehören die UBS Global Healthcare Conference, die Stifel Healthcare Conference, die Jefferies London Healthcare Conference, die Piper Sandler Healthcare Conference, die Citi's Global Healthcare Conference und die Evercore HealthCONx Conference. Bei der Konferenz von Citi wird das Management an einer Podiumsdiskussion über 'Neue Antikörpermechanismen in der Onkologie' teilnehmen.
- None.
- None.
VANCOUVER, British Columbia, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
- UBS Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on November 12 in Rancho Palos Verdes, CA.
- Stifel 2024 Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on November 19 at 4:10 pm Eastern Time (ET) in New York, NY.
- Jefferies London Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on November 20-21 and a fireside chat on November 20 at 2:30 pm Greenwich Mean Time in London, UK.
- Piper Sandler 36th Annual Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and present on December 3 in New York, NY.
- Citi's 2024 Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a panel discussion titled: ‘Novel Antibody Mechanisms in Oncology’ on December 3 at 3:15 pm ET in Miami, FL.
- 7th Annual Evercore HealthCONx Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on December 4 at 7:55 am ET in Coral Gables, FL.
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. and China.
Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
FAQ
What investor conferences will Zymeworks (ZYME) attend in November 2024?
What events will Zymeworks (ZYME) participate in during December 2024?
What panel discussion will Zymeworks (ZYME) participate in at Citi's 2024 Global Healthcare Conference?
Where will the Jefferies Healthcare Conference 2024 featuring Zymeworks (ZYME) take place?
